フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
UTILITY Therapeutics Joins Antimicrobials Working Group PR Newswire WASHINGTON, Feb. 17, 2021 WASHINGTON, Feb. 17, 2021 /PRNewswire/ -- The...
Shares in antibiotics developer Summit Therapeutics PLC were cancelled in London on Monday, a condition of its USD50 ...
AIM 24 February 2020 NOTICE 24/02/2020 NOTICE OF CANCELLATION OF ADMISSION TO TRADING ON AIM - XLON At the request of the Company the following...
FTSE Russell 17 February 2020 Summit Therapeutics (UK): Constituent Deletion Changes in FTSE UK Index Series 17 February 2020 Subject to the...
M Summit Therapeutics plc ("Summit Therapeutics" or the "Company") AIM Delisting Reminder Oxford, UK, and Cambridge, MA, US...
M Summit Therapeutics plc ("Summit Therapeutics" or the "Company") Notification of Transaction of Persons Discharging...
Summit Therapeutics PLC on Thursday said it has achieved the first USD1 million milestone payment under its license a ...
M Summit Therapeutics plc ('Summit' or the 'Company') Summit Therapeutics to Receive $1.0 Million Milestone Payment from...
M Summit Therapeutics plc ('Summit' or the 'Company') Summit Therapeutics to Present at the 2020 BIO CEO & Investor...
M Summit Therapeutics plc ('Summit' or the 'Company') Exercise of Restricted Stock Units Oxford, UK, and Cambridge, MA, US, 27...
Summit Therapeutics PLC on Friday said its chief operating officer and chief medical officer David Roblin will resign ...
M Summit Therapeutics plc ('Summit' or the 'Company') Summit Announces Management Update Oxford, UK, and Cambridge, MA, US, 24...
Summit Therapeutics PLC on Thursday said it secured an additional USD8.8 million funding award from Biomedical Advanc ...
M Summit Therapeutics plc ('Summit' or the 'Company') Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to...
M TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約